Disease Burden That Spans a Continuum
Haematology is unusual among therapeutic areas because it covers everything from a $4-a-month generic tablet to a $2.2 million one-time gene therapy, often for conditions that share little except that they originate in the bone marrow or the clotting cascade. Venous thromboembolism and atrial fibrillation affect tens of millions of Americans and drive enormous volumes of direct oral anticoagulants. Multiple myeloma, with roughly 35,000 new US diagnoses a year according to American Cancer Society estimates, has become one of oncology's most commercially dense subfields. Sickle cell disease affects around 100,000 Americans, disproportionately Black patients, and hemophilia A and B combined affect fewer than 30,000, yet both now command therapies priced above $2 million per patient. Myelodysplastic syndromes, chronic lymphocytic leukemia, paroxysmal nocturnal hemoglobinuria and acute myeloid leukemia round out a therapeutic area where prevalence and price move in almost inverse proportion.
Small-Molecule Backbones and Biologics Redraw Treatment
The anticoagulation market is still dominated by two factor Xa inhibitors: Bristol Myers Squibb and Pfizer's Eliquis (apixaban) and Johnson & Johnson and Bayer's Xarelto (rivaroxaban), which together generate tens of billions of dollars annually and have displaced warfarin as first-line therapy for stroke prevention in atrial fibrillation and treatment of VTE.
In multiple myeloma, immunomodulatory drugs built on thalidomide chemistry, Bristol Myers Squibb's Revlimid (lenalidomide) and Pomalyst (pomalidomide), remain foundational, alongside proteasome inhibitors such as Takeda's Velcade (bortezomib) and Amgen's Kyprolis (carfilzomib). CD38-targeting antibodies, led by Johnson & Johnson's Darzalex (daratumumab), have become nearly universal backbone therapy across lines of treatment, generating over $11 billion in 2024 sales for J&J alone.
Chronic lymphocytic leukemia and mantle cell lymphoma treatment has been reshaped by BTK inhibitors, AbbVie and Johnson & Johnson's Imbruvica (ibrutinib), AstraZeneca's Calquence (acalabrutinib) and BeiGene's Brukinsa (zanubrutinib), competing alongside AbbVie and Roche's BCL-2 inhibitor Venclexta (venetoclax). Chronic myeloid leukemia, once a death sentence, is now managed chronically with BCR-ABL tyrosine kinase inhibitors, Novartis's Gleevec and Tasigna, Bristol Myers Squibb's Sprycel, and Novartis's newer allosteric inhibitor Scemblix (asciminib), which is taking share in patients who fail or cannot tolerate earlier-generation TKIs.
Complement inhibition has carved out a durable niche in PNH and other rare haemolytic disorders through AstraZeneca's Soliris and its longer-acting successor Ultomiris (both eculizumab-family antibodies), now facing competition from Apellis Pharmaceuticals' Empaveli (pegcetacoplan) and Novartis's oral factor B inhibitor Fabhalta (iptacopan), which received FDA approval for PNH in 2023 and has since expanded into IgA nephropathy.
Cellular and Gene Therapies Move From Promise to Market
Multiple myeloma has become the proving ground for both CAR-T and bispecific antibodies. Bristol Myers Squibb and 2seventy bio's Abecma and Johnson & Johnson and Legend Biotech's Carvykti compete for BCMA-directed CAR-T share, with Carvykti's 2024 approval in earlier lines intensifying the fight. Bispecifics, Johnson & Johnson's Tecvayli and Talvey and Pfizer's Elrexfio, offer off-the-shelf convenience against cell therapy's manufacturing lag, and this dynamic is likely to define pricing and access strategy through the rest of the decade.
Sickle cell disease saw its first curative approvals in December 2023: Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy, the first CRISPR-edited therapy cleared by FDA, and bluebird bio's Lyfgenia, a lentiviral gene therapy. Both carry list prices above $2 million and both have launched slowly, constrained by the need for myeloablative conditioning, specialized treatment centers and payer utilization management, a pattern that echoes hemophilia gene therapy uptake for CSL Behring's Hemgenix (etranacogene dezaparvovec) and BioMarin's Roctavian (valoctocogene roxaparvovec), both of which have underperformed initial commercial expectations despite curative potential.
The Patent Cliff Reshaping Cash Flows
Revlimid's collapse is the cautionary tale the rest of the field is watching. Bristol Myers Squibb's myeloma franchise lost roughly $6 billion in annual revenue within two years of generic entry beginning in 2022 under a settlement schedule negotiated with Natco Pharma, Dr. Reddy's and Teva, among others, forcing the company to lean harder on Darzalex, Abecma and Breyanzi to backfill the gap.
Eliquis faces its own reckoning: Bristol Myers Squibb and Pfizer settled patent litigation to allow generic entry beginning in 2028, but the drug is also one of the first ten products selected for Medicare price negotiation under the Inflation Reduction Act, with a negotiated price taking effect in January 2026, compressing net revenue even before generics arrive. Xarelto faces a similar squeeze, with negotiated Medicare pricing also effective in 2026 ahead of expected generic entry around 2027.
Imbruvica, AbbVie's BTK franchise, has already seen US sales erode sharply as newer BTK inhibitors and generic threats converge, dropping from a peak above $5 billion to roughly half that by 2024. Incyte's Jakafi (ruxolitinib), a JAK inhibitor used in myelofibrosis and polycythemia vera, still carries patent protection into the late 2020s, but the company has been vocal about preparing its pipeline, including the JAK/CDK9 combination candidates, for the eventual cliff.
Where the Pipeline Is Heading
Three trends define haematology's next five years. First, oral factor XI inhibitors, Bayer and Johnson & Johnson's asundexian and Anthos Therapeutics' abelacimab, are advancing through Phase 3 trials aiming to separate anticoagulation from bleeding risk more cleanly than DOACs, a potential reset of the anticoagulant market just as Eliquis and Xarelto face genericization.
Second, menin inhibitors are opening a genuinely new mechanism in acute myeloid leukemia. Syndax Pharmaceuticals and Kura Oncology's revumenib won FDA approval in late 2024 for KMT2A-rearranged leukemia, and rivals including Syndax's own follow-on programs and Biomea Fusion are pushing into broader AML populations, a segment that has seen little mechanistic innovation since FLT3 inhibitors like Astellas's Xospata arrived.
Third, gene editing is moving beyond monogenic disorders. Following Casgevy's approval, companies including Editas Medicine and Beam Therapeutics are pursuing next-generation base-editing approaches intended to simplify conditioning regimens and shorten hospital stays, the biggest practical barrier to sickle cell and beta-thalassemia gene therapy uptake. If manufacturing and reimbursement infrastructure catch up to the science, haematology's curative segment could finally scale past its current status as a headline-grabbing but commercially marginal niche, even as its legacy small-molecule backbone faces the most severe patent erosion the field has seen in a decade.